Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing
- PMID: 15956985
- DOI: 10.1038/sj.npp.1300790
Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing
Abstract
The opioid antagonist nalmefene offers an alternative to traditional pharmacological treatments for alcoholism. The present study was designed to investigate the relationship between nalmefene plasma concentration and central mu-opioid receptor occupancy after a clinically effective dose (20 mg, orally). Pharmacokinetics and mu-opioid receptor occupancy of nalmefene after single and repeated dosing over 7 days was studied in 12 healthy subjects. Serial blood samples were obtained after both dosings, and pharmacokinetic parameters for nalmefene and main metabolites were determined. Central mu-opioid receptor occupancy of nalmefene was measured with positron emission tomography (PET) and [(11)C]carfentanil at four time points (3, 26, 50, 74 h) after both dosings. Nalmefene was rapidly absorbed in all subjects. The mean t(1/2) of nalmefene was 13.4 h after single and repeated dosing. The accumulation of nalmefene and its main metabolites in plasma during the repeated dosing period was as expected for a drug with linear pharmacokinetics, and steady-state was reached for all analytes. Both nalmefene dosings resulted in a very high occupancy at mu-opioid receptors (87-100%), and the decline in the occupancy was similar after both dosings but clearly slower than the decline in the plasma concentration of nalmefene or metabolites. High nalmefene occupancy (83-100%) persisted at 26 h after the dosings. The prolonged mu-opioid receptor occupancy by nalmefene indicates slow dissociation of the drug from mu-opioid receptors. These results support the rational of administering nalmefene when needed before alcohol drinking, and they additionally suggest that a high mu-opioid receptor occupancy can be maintained when nalmefene is taken once daily.
Similar articles
-
Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.Br J Clin Pharmacol. 2016 Feb;81(2):290-300. doi: 10.1111/bcp.12805. Epub 2016 Jan 27. Br J Clin Pharmacol. 2016. PMID: 26483076 Free PMC article.
-
Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system.J Nucl Med. 1997 Nov;38(11):1726-31. J Nucl Med. 1997. PMID: 9374341 Clinical Trial.
-
The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.Alcohol Clin Exp Res. 1998 Dec;22(9):2174-85. Alcohol Clin Exp Res. 1998. PMID: 9884166
-
Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.Expert Opin Pharmacother. 2016;17(4):619-26. doi: 10.1517/14656566.2016.1146689. Epub 2016 Feb 16. Expert Opin Pharmacother. 2016. PMID: 26810044 Review.
-
[Pharmacological profile and clinical findings of nalmefene (Selincro®) for reducing alcohol consumption in patients with alcohol dependence].Nihon Yakurigaku Zasshi. 2020;155(2):113-119. doi: 10.1254/fpj.19136. Nihon Yakurigaku Zasshi. 2020. PMID: 32115477 Review. Japanese.
Cited by
-
The Pharmacokinetics of Subcutaneous Methylnaltrexone Bromide in Rhesus Macaques (Macaca mulatta).J Am Assoc Lab Anim Sci. 2023 May 1;62(3):260-266. doi: 10.30802/AALAS-JAALAS-22-000111. Epub 2023 Apr 20. J Am Assoc Lab Anim Sci. 2023. PMID: 37080736 Free PMC article.
-
Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder.Psychopharmacology (Berl). 2021 Aug;238(8):2179-2189. doi: 10.1007/s00213-021-05842-7. Epub 2021 Apr 12. Psychopharmacology (Berl). 2021. PMID: 33846866 Free PMC article. Clinical Trial.
-
Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?Front Mol Neurosci. 2019 Oct 18;12:255. doi: 10.3389/fnmol.2019.00255. eCollection 2019. Front Mol Neurosci. 2019. PMID: 31680859 Free PMC article. Review.
-
Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.Neuropsychopharmacology. 2019 Aug;44(9):1667-1673. doi: 10.1038/s41386-019-0368-x. Epub 2019 Mar 13. Neuropsychopharmacology. 2019. PMID: 30867551 Free PMC article. Clinical Trial.
-
Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood.Br J Pharmacol. 2016 Aug;173(16):2490-505. doi: 10.1111/bph.13526. Epub 2016 Jul 18. Br J Pharmacol. 2016. PMID: 27238566 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials